Pharma supply chains suffer on regulations

Regulatory pressures are at the top of the list of supply chain concerns voiced by pharmaceutical manufacturers in an annual UPS poll. Among respondents with more than $1 billion in sales, an increased regulatory burden was the top concern of 56 percent, while this factor topped the list for a third of smaller drugmakers. Report

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.